12900 Results (Page 507 of 516)
All Market Research Reports
France Congestive Heart Failure Therapeutics Market Analysis
The France Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $283 Mn in 2022 to $412 Mn by 2030, with a CAGR of 4.8% during the forecast period of 2022-2030. The key drivers in France include the aging population, contributing to an increased demand for CHF treatments, ongoing advancements in pharmaceutical research leading to innovative therapies, and government initiatives and reimbursement policies supporting accessibility. The France Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, Servier, Amgen, Otsuka Pharmaceuticals, Lexicon Pharmaceuticals, Tenex Therapeutics, etc, among various others.
Egypt Biosensors Market Analysis
The Egypt Biosensors Market was valued at $80.9 Mn in 2023 and is predicted to grow at a CAGR of 9.5% from 2023 to 2030, to $152.7 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, aging population, and growing demand for Point-of-Care (POC) testing. The prominent players of the Egypt Biosensors Market are BM-Egypt, Kimal, Medtronic, Abbot Laboratories, and Johnson & Johnson, among others
China Digital Biomarkers Market Analysis
China Digital Biomarkers Market was valued at $233.12 Mn in 2023 and is predicted to grow at a CAGR of 23.8% from 2023 to 2030, to $1,039.03 Mn by 2030. The key drivers of this industry include the rising burden of chronic diseases, government initiatives, and a focus on personalized medicine. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
UAE Medication Access Programs Market Analysis
The UAE Medication Access Programs Market was valued at $27.4 Mn in 2023 and is predicted to grow at a CAGR of 15.6% from 2023 to 2030, to $75.7 Mn by 2030. The key drivers of this industry include increasing healthcare expenditure, government initiatives, and the rising prevalence of chronic disease. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
China Cancer Induced Bone Disease Therapeutics Market
China Cancer Induced Bone Disease Therapeutics Market valued at $105 Mn in 2022, projected to reach $184 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancers, government initiatives, and untapped market potential. The industry is primarily dominated by players such as Siemen, Hengrui, Shanghai Pharma, Johnson & Johnson, Novartis, and Amgen among others.
Indonesia Congestive Heart Failure Therapeutics Market Analysis
The Indonesia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $62 Mn in 2022 to $97 Mn by 2030, with a CAGR of 5.8% during the forecast period of 2022-2030. The growth of the Indonesia Congestive Heart Failure Therapeutics Market is driven by the increasing prevalence of cardiovascular conditions among an aging population, government initiatives enhancing accessibility and affordability, and the potential for healthcare infrastructure improvements, particularly in rural areas. The Indonesia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, Sanofi, AstraZeneca, Bayer, Eli Lilly, Merck, Kalbe Pharma, Kimia Pharma, Pharos, Indopharma, etc., among various others.
France Biosensors Market Analysis
The France Biosensors Market was valued at $794.8 Mn in 2023 and is predicted to grow at a CAGR of 7.0% from 2023 to 2030, to $1276.2 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the France Biosensors Market are Villard Medical, Bio-Rad International, Masimo Corporation, Meridian Bioscience, and Biosensors International, among others.
Indonesia Digital Biomarkers Market Analysis
Indonesia Digital Biomarkers Market was valued at $17.40 Mn in 2023 and is predicted to grow at a CAGR of 22.3% from 2023 to 2030, to $71.21 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, government initiatives, and a growing focus on preventative care. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Brazil Medication Access Programs Market Analysis
The Brazil Medication Access Programs Market was valued at $137.2 Mn in 2023 and is predicted to grow at a CAGR of 15.6% from 2023 to 2030, to $378.6 Mn by 2030. The key drivers of this industry include the high prevalence of chronic disease, the large uninsured population, and government initiatives. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
Canada Cancer Induced Bone Diseases Therapeutics Market
Canada Cancer Induced Bone Disease Therapeutics Market valued at $104 Mn in 2022, projected to reach $163 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include rising cancer incidence, increased research and development, and advancements in cancer diagnostics. The industry is primarily dominated by players such as Amgen, Pfizer, Merck, Eli Lilly, Novartis, Bayer, and Johnson & Johnson, among others.
Japan Congestive Heart Failure Therapeutics Market Analysis
The Japan Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $640 Mn in 2022 to $1,044 Mn by 2030, with a CAGR of 6.3% during the forecast period of 2022-2030. The primary driving factors include the growing emphasis on quality of life, technological developments in medicine that provide novel therapeutic approaches, and the rising incidence of heart failure as a result of aging populations and sedentary lifestyles in Japan. The Japan Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Merck, Pfizer, Boehringer Ingelheim, Otsuka, Sumitomo Pharma, Eisai, Meiji Seika Pharma, etc, among various others.
Germany Biosensors Market Analysis
The Germany Biosensors Market was valued at $1057.7 Mn in 2023 and is predicted to grow at a CAGR of 6.2% from 2023 to 2030, to $1611.6 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the Germany Biosensors Market are Lifesensors, Siemens Healthcare, B. Braun Melsungen AG, Meridian Bioscience, and Biosensors International, among others.
Japan Digital Biomarkers Market Analysis
Japan Digital Biomarkers Market was valued at $180.26 Mn in 2023 and is predicted to grow at a CAGR of 22.8% from 2023 to 2030, to $759.08 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, the aging population, and the focus on innovation. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Mexico Medication Access Programs Market Analysis
The Mexico Medication Access Programs Market was valued at $82.3 Mn in 2023 and is predicted to grow at a CAGR of 14.85% from 2023 to 2030, to $217 Mn by 2030. The key drivers of this industry include healthcare reforms, disease burden, and government support. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
Canada Car T-Cell Therapy Market
Canada Car T-Cell Therapy Market valued at $232 Mn in 2022, projected to reach $393 Mn by 2030 with a 6.8% CAGR. The growing occurrence and prevalence of cancer worldwide, driven by factors like population aging, unhealthy lifestyles, and environmental influences, contribute to an expanding pool of patients who may potentially benefit from CAR T-Cell therapy, thereby expanding the market for this treatment. The top pharmaceutical entities presently operating in the market are Gilead Sciences (Kite Pharma), Novartis, Bristol Myers Squibb, Celgene, Johnson & Johnson, Cellectis, Atara Biotherapeutics, Adaptimmune Therapeutics, Poseida Therapeutics and UCAR-T.
Malaysia Congestive Heart Failure Therapeutics Market Analysis
The Malaysia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $17 Mn in 2022 to $26 Mn by 2030, with a CAGR of 6% during the forecast period of 2022-2030. The market in Malaysia is driven by the escalating incidence due to aging demographics and unhealthy lifestyle choices, supported by proactive government initiatives to enhance healthcare accessibility and affordability, along with the expanding coverage of CHF medications by insurance policies. Malaysia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Abbott, Roche, Merck, DuoPharma, Pharmaniaga, Hovid, Apex Bio, etc., among various others.
India Biosensors Market Analysis
The India Biosensors Market was valued at $525.6 Mn in 2023 and is predicted to grow at a CAGR of 11% from 2023 to 2030, to $1091.2 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, increasing demand for accurate disease diagnosis, and growing demand for Point-of-Care (POC) testing. The prominent players of the India Biosensors Market are i- SENS, SD Biosensor, Fortune Biosolutions, Glowvista Instruments, and Healthium Medtech, among others.
Malaysia Digital Biomarkers Market Analysis
Malaysia Digital Biomarkers Market was valued at $4.66 Mn in 2023 and is predicted to grow at a CAGR of 22.5% from 2023 to 2030, to $19.30 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, government initiatives, rising healthcare costs, and an aging population. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
France Medication Access Programs Market Analysis
The France Medication Access Programs Market was valued at $151 Mn in 2023 and is predicted to grow at a CAGR of 13.6% from 2023 to 2030, to $368.6 Mn by 2030. The key drivers of this industry include healthcare policies, increasing chronic diseases, and technological advancements. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
US Car T-Cell Therapy Market
US Car T-Cell Therapy Market valued at $1,218 Mn in 2022, projected to reach $1,772 Mn by 2030 with a 4.8% CAGR. The rising global cancer incidence, driven by aging populations, unhealthy lifestyles, and environmental factors, fuels an expanding population eligible for CAR T-Cell therapy, contributing to the growth of its market. Currently, leading pharmaceutical companies in this market include Gilead Sciences, Novartis, Bristol Myers Squibb, Johnson & Johnson, Kite Pharma, Legend Biotech, Celgene, Cellectis, Atara Biotherapeutics, and UCAR-T.
Mexico Congestive Heart Failure Therapeutics Market Analysis
The Mexico Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $155 Mn in 2022 to $247 Mn by 2030, with a CAGR of 6.05% during the forecast period of 2022-2030. The key drivers of the market include the demographic trend of an aging population, lifestyle-related factors contributing to an increased incidence of heart failure, ongoing advancements in pharmaceutical research leading to novel therapies, and the significant impact of government initiatives. The Mexico Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, Pfizer, Roche, Sanofi, PISA, Sanfer, Genomma Lab, etc, among various others.
Mexico Exosome Research Market Analysis
The Mexico Exosome Research Market was valued at $2.5 Mn in 2023 and is projected to grow at a CAGR of 16.25% from 2023 to 2023, to $7.3 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, NanoSomix, NX Pharmagen, Exosome Diagnostics among others.
Philippines Digital Biomarkers Market Analysis
Philippines Digital Biomarkers Market was valued at $6.38 Mn in 2023 and is predicted to grow at a CAGR of 22.8% from 2023 to 2030, to $26.87 Mn by 2030. The key drivers of this industry include the rising burden of chronic diseases, government initiatives, growing focus on preventative care, and the aging population. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Germany Medication Access Programs Market Analysis
The Germany Medication Access Programs Market was valued at $200.9 Mn in 2023 and is predicted to grow at a CAGR of 12.8% from 2023 to 2030, to $466.9 Mn by 2030. The key drivers of this industry include healthcare expenditure, the aging population, and pharmaceutical support. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
Vietnam Cardiac Resynchronization Therapy Market
Vietnam Cardiac Resynchronization Therapy Market valued at $24 Mn in 2022, projected to reach $36 Mn by 2030 with a 5.23% CAGR. The notable increase in heart failure cases worldwide, propelled by aging demographics and lifestyle-associated cardiovascular ailments, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.